Clinical Trials
Clinical Trials Office (CTO)
The Clinical Trials Office within the Carole and Ray Neag Comprehensive Cancer Center is focused on supporting high-quality cancer research and thus helping promote better care for cancer patients at UConn Health. The staff consists of highly qualified, trained, and certified professionals who are committed to assisting in the planning, development, implementation, and regulatory oversight of all phases of cancer clinical trials.
The office was created under the Medical Directorship of Pramod K. Srivastava, Ph.D., M.D., and Director of the Cancer Center and provides a dedicated team to enable Hematology and Medical Oncology faculty to bring to UConn Health innovative treatment options that otherwise would not be available to cancer patients. The Clinical Trials Office actively partners with various cancer cooperative groups, pharmaceutical firms, and other academic centers to bring revolutionary cancer research studies to UConn Health. By supporting clinical research, the office aids UConn Health in meeting its goals of excellence in patient care, education, and research. It also engages with other cancer research programs within UConn Health to reach out to the community to educate patients about clinical trials, create awareness of cancer prevention, and increase patient participation in clinical trials.
Current Membership Status
- Cancer Trials Support Unit (CTSU)
- Academic and Community Cancer Research United (ACCRU)
Current Therapeutic Studies Opened to Accrual
- GBT 133- An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial (PI: Biree Andemariam)
- Forma Therapeutics: An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Agonist in Subjects With Sickle Cell Disease (PRAISE). (PI: Biree Andemariam)
- An Open-Label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamisc, and Safety of Orally Administered Epeleuton in Patients with Sickle Cell Disease (PI: Biree Andemariam)
- A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide (PI: Kumar Swarup)
- A multicenter, randomized, prospective double-blind, cross-over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) (PI: Alex Merkulov)
- Forma Therapeutics: An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Agonist in Subjects With Sickle Cell Disease (PRAISE)
- Randomized Controlled Trial Assessing Transperineal Prostate Biopsy to Reduce Infection Complications
Current Non-Therapeutic Studies Opened to Accrual
- A Prospective Multicenter Study of Transbronchial Microwave Ablation Using Robotic-Assisted Bronchoscopy in Patients with Oligometastatic Tumors in the Lung (PI: Omar Ibrahim)
- Optellum data collection protocol lung nodules. PI: Omar Ibrahim
- TREXIT Randomized controlled trial assessing transperineal prostate biopsy to reduce infection complications (PI: Benjamin Ristau)
- Oxbryta® Product Registry: An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals with SCD (PROSPECT) (PI: Biree Andemariam)
- Measurement of Complex Viscoelasticity of Sickle, Normal and Hypoxic Red Blood Cell Mixtures in Sickle Plasma: Implications for Transfusion Therapy (PI: Biree Andemariam)
- Bone Loss, Physical Function and Frailty in Older Women with Sickle Cell Trait (Bone Loss SCT Study) (PI: Biree Andemariam)
Our Team
Margaret Callahan, M.D., Ph.D.
Clinical Trials Office Medical Director
Juliette Dudek, B.S.
Clinical Trials Office Administrative Manager
Quratulain Ali, M.P.H., CCRP, MSHS
Clinical Trials Office Supervisor
Kristen Grandonico, M.P.H.
Clinical Research Associate
Katarzyna Nastri, B.A., CCRP
Clinical Research Associate, Compliance and Quality
Madison Lowe, B.S.
Clinical Research Assistant
Jillian McNamara, B.S., M.P.H.
Clinical Research Assistant
Maria Ortiz, M.P.H., Ph.D. Student
Clinical Research Associate
Vincent Rella
Fiscal Coordinator
About Clinical Trials
Clinical trials are research studies in which real people participate as volunteers. Clinical research studies (also known as clinical trials) are designed to evaluate health risks and to test new approaches to the diagnosis, treatment and prevention of specific diseases. These studies play a significant role in the development of new treatments and medications for various diseases and conditions. A clinical trial could be a treatment option for you.
The goal of research is to find better ways to treat or identify cancer and help cancer patients. Clinical trials test many types of treatment, such as new drugs, new approaches to surgery or radiation therapy, new combinations of treatments, or new methods such as gene therapy. Some clinical trials study the effects of our standard treatments on patient quality of life during and after completion of the treatment. The knowledge that may be gained from this type of work can be of great value to our society.
To ensure the safety of volunteers who enroll in clinical studies, each project must be approved by an Institutional Review Board (IRB). The goal of the IRB is to ensure safety, welfare and well-being of study participants. During the review process, the IRB evaluates the potential risks and benefits associated with the study and decide whether or not to approve it.
This information is provided by the National Library of Medicine (NLM).